KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Cash (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Change in Cash for 6 consecutive years, with $86.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash fell 48.1% year-over-year to $86.8 million, compared with a TTM value of $150.9 million through Dec 2025, down 25.15%, and an annual FY2025 reading of $150.9 million, down 25.15% over the prior year.
  • Change in Cash was $86.8 million for Q4 2025 at Recursion Pharmaceuticals, down from $133.3 million in the prior quarter.
  • Across five years, Change in Cash topped out at $423.8 million in Q2 2021 and bottomed at -$238.0 million in Q3 2021.
  • Average Change in Cash over 5 years is $24.3 million, with a median of -$9.4 million recorded in 2022.
  • The sharpest move saw Change in Cash tumbled 2615.0% in 2023, then skyrocketed 3863.8% in 2024.
  • Year by year, Change in Cash stood at -$109.6 million in 2021, then surged by 185.97% to $94.2 million in 2022, then crashed by 95.52% to $4.2 million in 2023, then surged by 3863.8% to $167.2 million in 2024, then plummeted by 48.1% to $86.8 million in 2025.
  • Business Quant data shows Change in Cash for RXRX at $86.8 million in Q4 2025, $133.3 million in Q3 2025, and $24.7 million in Q2 2025.